DocGo (NASDAQ:DCGO) Earns “Buy” Rating from Needham & Company LLC

DocGo (NASDAQ:DCGO)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research note issued on Wednesday, Benzinga reports.

A number of other research analysts also recently commented on DCGO. Canaccord Genuity Group reiterated a “hold” rating and set a $1.00 target price on shares of DocGo in a research report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DocGo in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.38.

DocGo Price Performance

Shares of NASDAQ DCGO traded up $0.03 during midday trading on Wednesday, reaching $0.40. 652,104 shares of the stock traded hands, compared to its average volume of 884,416. The stock has a market capitalization of $39.55 million, a PE ratio of -0.20 and a beta of 0.94. DocGo has a one year low of $0.31 and a one year high of $1.65. The company’s 50 day moving average is $0.48 and its 200 day moving average is $0.56.

DocGo (NASDAQ:DCGO) last posted its earnings results on Monday, August 17th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06). The firm had revenue of $73.42 million for the quarter, compared to the consensus estimate of $75.35 million. DocGo had a negative net margin of 65.29% and a negative return on equity of 40.42%. As a group, equities analysts forecast that DocGo will post -0.22 EPS for the current year.

Institutional Trading of DocGo

A number of institutional investors have recently bought and sold shares of the stock. S Squared Technology LLC bought a new stake in DocGo in the second quarter worth $1,060,725. Renaissance Technologies LLC lifted its position in DocGo by 167.1% in the first quarter. Renaissance Technologies LLC now owns 1,510,361 shares of the company’s stock worth $950,000 after buying an additional 944,826 shares during the last quarter. BlackRock Inc. bought a new stake in DocGo in the second quarter worth $750,000. Isthmus Partners LLC lifted its position in DocGo by 14.0% in the first quarter. Isthmus Partners LLC now owns 1,013,056 shares of the company’s stock worth $637,000 after buying an additional 124,211 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in DocGo in the second quarter worth $517,000. 56.44% of the stock is currently owned by institutional investors.

About DocGo

DocGo Inc (NASDAQ: DCGO) is a healthcare services and technology company that delivers medical care and transportation outside traditional clinical settings. Its platform combines mobile clinical services, technology-enabled care coordination and non-emergency medical transportation to help healthcare providers, government agencies, insurers and employers serve patients in their homes and communities.

The company’s services include ambulance and non-emergency medical transportation, mobile primary and urgent care, remote patient monitoring, diagnostic testing, vaccination programs and community-based healthcare.